-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Downgrades Legend Biotech to Perform, Lowers Price Target to $40

Benzinga·08/12/2026 14:55:02
Listen to the news
Oppenheimer analyst Trevor Allred downgrades Legend Biotech (NASDAQ:LEGN) from Outperform to Perform and lowers the price target from $75 to $40.